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CD4+/CD25+ regulatory T cells (T reg cells) 
are important in the induction of immunologi-
cal tolerance (1). The elimination of this popula-
tion enhances immune responses to alloantigens, 
favoring the rejection of tissue grafts (2), spon-
taneous appearance of autoimmune diseases, and 
infl  ammation (3). T reg cells also suppress natural 
immune responses to parasites (4) and viruses (5) 
and inhibit or attenuate antitumor immunity in-
duced by cancer vaccines. The X chromosome–
encoded forkhead transcription factor Foxp3 is 
uniquely expressed by T reg cells, serves as a lin-
eage specifi  cation factor, and confers suppres-
sive function to these cells (6–8). However, the 
intracellular location of Foxp3 limits its useful-
ness in studying and purifying this subpopulation. 
Cell surface expression of CD25 expression is 
often used as a marker for CD4+ T reg cells, 
but CD25 is somewhat nonspecifi  c, as it is also 
up-regulated on other CD4+ T cell populations 
after activation.
Putative mechanisms of suppression by T reg 
cells remain ill defi  ned but include cell–cell con-
tacts considered predominant in vitro and the 
release of soluble mediators predominant in vivo. 
Surface molecules linked to T reg cell suppres-
sion include CTLA-4 (9, 10), chemokine recep-
tors (CCR4 and CCR8; reference 11), selectins 
(CD62L; reference 12), integrins (CD103; ref-
erence 13), and CD127 (14). In vivo, putative 
mechanisms include the release of soluble fac-
tors IL-10 and TGF-β (15, 16). Recently, other 
T reg cell Foxp3-dependent suppressor functions 
have been suggested by gene clustering experi-
ments (8). Moreover, the deletion of Foxp3 re-
sults in the reduced expression of such putative 
suppressor genes (17).
Extra- and/or immediate pericellular accu-
mulation of adenosine elicits immunosuppres-
sive cellular responses that are mediated through 
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markers and an inability to defi  ne mechanisms of suppression. We show that the expression 
of CD39/ENTPD1 in concert with CD73/ecto-5′-nucleotidase distinguishes CD4+/CD25+/
Foxp3+ T reg cells from other T cells. These ectoenzymes generate pericellular adenosine 
from extracellular nucleotides. The coordinated expression of CD39/CD73 on T reg cells and 
the adenosine A2A receptor on activated T effector cells generates immunosuppressive 
loops, indicating roles in the inhibitory function of T reg cells. Consequently, T reg cells 
from Cd39-null mice show impaired suppressive properties in vitro and fail to block allo-
graft rejection in vivo. We conclude that CD39 and CD73 are surface markers of T reg 
cells that impart a specifi  c biochemical signature characterized by adenosine generation 
that has functional relevance for cellular immunoregulation.
CORRESPONDENCE
Terry B. Strom: 
tstrom@bidmc.harvard.edu
OR 
Simon C. Robson: 
srobson@bidmc.harvard.edu
S. Deaglio, K.M. Dwyer, and W. Gao contributed equally to 
this paper.
T.B. Strom and S.C. Robson contributed equally to this paper.
S. Deaglio’s present address is Dept. of Genetics, Biology, and 
Biochemistry and CeRMS, University of Torino Medical 
School, 10126 Torino, Italy.
This work was presented, in part, at the Keystone Symposium 
on Regulatory T cells in Vancouver, Canada in February 2007.1258  GENERATION OF ADENOSINE BY T REG CELLS | Deaglio et al. 
several type 1 purinergic (adenosine) receptors, including A2A 
(18). Seminal, important genetic data indicate that adenosine, 
which is operative via the A2A adenosine receptor, plays 
critical, nonredundant, autonomous, and autochthonous roles 
in inhibiting eff  ector functions of activated T cells (19, 20). 
Modulation of infl  ammation by adenosinergic mechanisms 
has been rigorously tested in models of T cell–dependent 
autoimmune and viral hepatitis (21) and in antitumor T cell 
immunity (22). In addition, the stimulation of A2A-mediated 
responses modulates the control of T cell–mediated colitis in 
experimental mouse models by suppressing the expression of 
proinfl  ammatory cytokines in a manner independent of both 
IL-10 and TGF-β (23).
We have proposed that the regulation of extracellular 
nucleotide catabolism by T reg cells might be responsible 
for the coordination of such adenosinergic eff  ects. Conse-
quently, we have investigated the regulation of extracellular 
nucleotide catabolism by T reg cells that ultimately leads 
to the generation of pericellular adenosine. The rate-limiting 
step of this ectonucleotidase cascade is determined by CD39 
(ENTPD1 [ectonucleoside triphosphate diphosphohydrolase-1]; 
EC 3.6.1.5), an ectoenzyme that hydrolyzes ATP/UTP and 
Figure 1.  CD4+/CD25+ cells express CD39. (A) The expression of 
CD39 (open profi  les) on mouse lymph node cell suspensions is shown 
in the histograms on the right, contrasted against control IgG (gray). 
The expression of CD39 on CD4+, CD8+, and B220+ subsets is shown 
in the density plots. (B) Lymph node cells were stained with CD4-Cy5 
and CD25-PE. CD39 expression in gated populations is shown in the 
  histograms (open) with irrelevant control (gray). (C) CD4+ cells were 
stained for CD39 (horizontal axis) and the indicated markers. (D) Real-
time PCR analysis in CD4+/CD39+ and CD4+/CD39− cells. (E) 5 × 104 
CD4+/CD25− T cells were mixed with CD4+/CD39+ or CD4+/CD25+ cells. 
[3H]Thymidine incorporation was measured after 3 d. Data are means with 
SEM (error bars) of three independent experiments.JEM VOL. 204, June 11, 2007  1259
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ADP/UDP to the respective nucleosides such as AMP. Extra-
cellular nucleoside monophosphates are, in turn, rapidly degraded 
to nucleosides, (e.g., adenosine) by soluble or membrane-
bound ecto-5′-nucleotidases (e.g., CD73 [EC 3.1.3.5]; refer-
ence 24). Ectonucleotidase biochemical activity has already 
been shown to be relevant in immune responses. Specifi  cally, 
CD39 expressed by Langerhans cells is critically involved in 
the suppression of infl  ammation (25). More   recently, CD73 
has been shown to be expressed by CD25+FoxP3+ T reg 
cells and CD25− uncommitted primed precursor T helper cells 
that, through the generation of adenosine, dampen infl  amma-
tory responses (26).
RESULTS AND D  I  S  C  U  S  S  I  O  N 
This study reports on the identifi  cation of CD39 together 
with CD73 as novel cell surface markers of CD4+ T reg cells. 
In addition to the expression of both ectonucleotidases by 
T reg cells, the robust generation of adenosine controlled 
by these ectoenzymes functionally distinguishes classic T reg 
cells from other CD4+ T cell populations. Our observations 
concerning extracellular adenosine production by T reg cells 
have been further developed by applying models conceived 
by Sitkovsky and others (19–22) that show that adenosine 
receptors on targeted T eff  ector cells mediate suppressive 
functions. Gavin et al. (8) predict from gene clustering mod-
els that there are at least three potential T reg cell mechanisms 
inclusive of “suppressive soluble factors, generation of extra-
cellular adenosine and release of reactive oxygen.” We dem-
onstrate in this study that alterations in pericellular levels of 
adenosine brought about by CD39 (and CD73) associated 
with T reg cells have a major, albeit not total, suppressive 
  eff  ect on cellular responses in vitro. We also show that CD39 
plays a nonredundant role in the suppressive capabilities of 
T reg cells in vivo, as demonstrated by the relative failure of 
Cd39-null T reg cells to block skin allograft rejection. We 
propose that cell-associated CD39 initiates and regulates the 
generation of adenosine and comprises an important compo-
nent of the suppressive machinery of T reg cells.
T reg cells express CD39
Rabbit anti–mouse CD39 polyclonal antibody was raised 
previously by cDNA immunization (27) and was used to 
stain mononuclear cells purifi  ed from lymph nodes (Fig. 1 A) 
and spleen (not depicted) of naive WT mice. CD39 is ex-
pressed by the majority of monocytes and by a subset of lym-
phocytes (Fig. 1 A) in C57BL/6 mice, as inferred by gating 
on forward scatter and side scatter. Among lymphocytes, the 
majority of CD39+ cells are B220+ B cells. The remaining 
CD39+ cells reside within the CD4+ subset, where they con-
sistently range from 8 to 12% of all CD4+ cells in lymph nodes 
and spleen (Fig. 1 A). Importantly, no cells within the CD8+ 
T cell subset express CD39.
Further characterization of resting C57BL/6 lymphocytes 
reveals that CD39 is predominantly expressed on those CD4+ 
cells that concurrently express CD25 (Fig. 1 B). CD39 is con-
sistently and abundantly expressed by CD4+/CD25high T cells, 
whereas the CD4+/CD25dim population shows a dichotomic 
pattern with respect to CD39 expression, with  50% of the 
cells being positive. Less than 1% of CD39+ cells are found 
within the CD4+/CD25− compartment (Fig. 1 B). Predomi-
nant expression of CD39 by CD4+/CD25+ T cells was also 
observed in other strains of mice such as BALB/c and, addi-
tionally, in primates and humans (unpublished data). Nearly 
all CD4+/CD39+ cells are also CD5high, CD45RBlow and are 
mostly CD62Llow (Fig. 1 C). CD4+/CD8−/CD25+ thymocytes 
express CD39 at equivalent amounts to peripheral CD4+/
CD25+ T cells (unpublished data).
RT-PCR analyses of sorted mouse cell populations con-
fi  rm that CD4+ cells express the highest levels of CD39 mRNA 
among lymphocytes (unpublished data). Gene expression 
pro  fi  ling of CD4+ T cells, which was sorted on the basis of 
CD39 cell surface expression, indicates that CD4+/CD39+ 
but not CD4+/CD39− T cells robustly express Foxp3, CD25, 
glucocorticoid-induced tumor necrosis factor receptor (GITR), 
and CTLA-4 transcripts, which is in keeping with the recog-
nized T reg cell phenotype (Fig. 1 D).
When functional properties are tested, CD4+/CD39+ 
cells are found to suppress CD4+/CD25− proliferation with 
an effi   cacy similar to that observed with classic naive CD4+/
CD25+ T reg cells (Fig. 1 E). In concordance with the T reg 
cell phenotype, CD4+CD39+ cells are nonresponsive to TCR 
stimulation in the presence of irradiated T-depleted   accessory 
cells and in the absence of IL-2 (unpublished data).
The incomplete overlap between CD4+/CD39+ and 
CD4+/CD25+ subsets is interesting given recent data dem-
on  strating that Foxp3 is expressed in a signifi  cant percent-
age of CD4+ cells that is potentially independent of CD25 
expression (7). Further work suggests that a combination of 
surface markers, including CD127, provides a more accurate 
defi  nition of T reg cells than CD25 alone (14). Lastly, CD39 
is one of 67 genes, as shown by gene profi  ling, to be highly 
associated with Foxp3 expression, even more so linked than 
CD25 (7). Indeed, Foxp3 amplifi  es and stabilizes the expres-
sion of genes encoding cell surface or secreted molecules 
(e.g., Fgl2, CD73, CD39, TRAIL, or CTLA4; reference 8).
To discern the relationship between CD39 expression, 
CD73, and the T reg cell phenotype-function relationships, 
we studied purifi  ed T cells from mice with the GFP reporter 
gene introduced into the endogenous Foxp3 locus (desig-
nated as Foxp3+(GFP+) knock-in cells; reference 28). The 
great majority ( 80%) of Foxp3+(GFP+) cells from spleen 
and lymph nodes strongly express CD39 (Fig. 2 A). CD39 is 
a more consistent and reliable marker for T reg cells than 
CD25; importantly, only  50% of Foxp3+(GFP+) knock-in 
cells also express CD25 (Fig. 2 A). However, a limited fraction 
of Foxp3−(GFP−) cells are also CD39+ (Fig. 2 A). Foxp3+/
CD39− cells are rarely seen and have been excluded from 
further analyses.
Therefore, three substantive populations can be defi  ned 
on the basis of diff  erential CD39 and Foxp3 expression: 
Foxp3+/CD39+, Foxp3−/CD39+, and Foxp3−/CD39−. These 
populations were sorted, and gene expression profi  les together 1260  GENERATION OF ADENOSINE BY T REG CELLS | Deaglio et al. 
with functional suppressive properties were determined. The 
Foxp3+/CD39+ fraction was shown to mirror the recog-
nized genetic profi  le of T reg cells, as defi  ned by the presence 
of Foxp3, GITR, CTLA-4, and IL-10 transcripts (Fig. 2 B). 
These Foxp3+/CD39+ cells also effi   ciently suppress CD4+/
CD25− proliferation in vitro (Fig. 2 C). Conversely, the 
Foxp3−/CD39+ subset contains T lymphocytes that appear 
to be associated with the memory compartment, pointing to 
a comparable derivation of T reg cells and other activated 
memory cells (unpublished data). As expected, the Foxp3−/
CD39− population expresses neither phenotypic nor func-
tional features of T reg cells (Fig. 2, B and C).
We next sought to determine the exact functional rela-
tionship between the capacity for adenosine generation and 
Foxp3 expression within recognized mouse CD4+ T cell pop-
ulations. Using Foxp3 knock-in mice, Foxp3+(GFP+) T reg 
cells were found to coexpress both ectonucleotidases CD39 
and CD73. This is a unique situation among T lymphocytes 
and provides precise phenotypic markers and designates bio-
chemical functions for T reg cells (Fig. 2 D). Consistent with 
the phenotypic data, RT-PCR analysis confi  rms that Foxp3+/
CD39+ cells exhibit high levels of the gene expression of both 
CD39 and CD73 (Fig. 2 D). Moreover, CD4+/CD39+/CD73+ 
cells have comparable suppressive properties to classic CD4+/
CD25+ cells in vitro (not depicted and Fig. 2 E).
T reg cells generate extracellular adenosine
CD39 and CD73 coexpression are associated with Foxp3+ 
T cells (Fig. 2 D). However, CD39 and CD73 are also typi-
cally expressed by monocytes and endothelial cells, in which 
altered expression can be linked to disordered circulatory ho-
meostasis, thrombosis, and platelet activation (29). Moreover, 
CD39 expression encompasses diff  erent cellular lineages, in-
cluding B lymphocytes and Langerhans cells, where it may play 
a role in modulating immune cell–cell contacts by catalyzing 
local changes in extracellular nucleotide-triggered responses 
(25). CD73 is more generally expressed on the vasculature by 
select T and B cell subsets, on follicular dendritic cells, and on 
thymic medullary reticular fi  broblasts together with various 
epithelial cells (24).
Figure 2.  Foxp3+ cells express CD39. (A) CD4+ T cells from Foxp3+
(GFP+) knock-in mice stained with CD25-PE or CD39-PE. (B) Real-time 
PCR analysis of Foxp3+/CD39+ (black bars), Foxp3−/CD39+ (shaded bars), 
and Foxp3−/CD39− (white bars) cells. (C) Foxp3+/CD39+ suppresses 
T effector (Foxp3−/CD39− CD4+) proliferation. [3H]Thymidine incorporation 
was measured after 72 h. Data are representative of two independent 
experiments, with error bars representing the SD of triplicate wells. 
(D) Foxp3+(GFP+) cells stained for CD39-APC and CD73-PE. (E) CD73 
mRNA expression in Foxp3+/CD39+ (black bars), Foxp3−/CD39+ (shaded bars), 
Foxp3−/CD39− (white bars), and B lymphocytes (striped bars).JEM VOL. 204, June 11, 2007  1261
BRIEF DEFINITIVE REPORT
The fi  nding that a population of CD4+ lymphocytes en-
dowed with suppressive functions selectively coexpresses CD39 
and CD73 illustrates potential functional roles of   extracellular 
nucleotide-metabolizing enzymes within the T cell pool. In 
the biochemical systems that we propose for T cell regulation, 
a degree of specifi  city could be dictated by three essential 
modulatory components: titrated and various nucleotide re-
lease into the extra- or pericellular milieu,   specifi  c receptors 
for these mediators, and, fi  nally, a varied repertoire of ecto-
nucleotidases upon regulatory and eff  ector cells.
CD39 biochemical activity is the rate-limiting compo-
nent of the ectoenzymatic chain that metabolizes  extracellular 
nucleoside di- and triphosphates, ultimately to the respective 
nucleosides, such as adenosine. Nucleoside triphosphate diphos-
phohydrolase (NTPDase) biochemical activity levels of intact 
WT CD4+/CD25+ T cells are 8–10 times greater than that of 
the CD4+/CD25− counterparts, constitutively not expressing 
CD39 (Fig. 3 A). Furthermore, using 14C-radiolabeled nucleo-
tides, we demonstrate that WT CD4+ cells rapidly hydrolyze 
exogenous ADP to effi   ciently generate adenosine in vitro. 
Cd39-null CD4+ cells show markedly diminished rates of ADP 
phosphohydrolysis with no production of adenosine (Fig. 3 B). 
These data confi  rm that functional, classic Foxp3+/T reg cells 
constitutively express CD39 and CD73 and that the biochemi-
cal pathway leading to the synthesis of adenosine is operative.
In contrast, the two other CD4+ subpopulations, namely 
Foxp3−/CD39+ and Foxp3−/CD39−, fail to generate aden-
osine from ADP (Fig. 3 C), which is in keeping with low 
CD73 expression levels. CD8+ T cells included as a CD39−/
CD73+ control do not generate adenosine. Therefore, within 
the T cell compartment, only the Foxp3+(GFP+) T reg cell 
possesses the intact ectonucleotidase catalytic machinery, and 
these properties are maintained during cellular activation (un-
published data). Such cells might dictate the generation of 
pericellular adenosine (at extravascular sites) to potentially 
mediate immunoregulation at a cellular level.
Adenosine suppresses T cell responses
The hypothesis that adenosine may comprise, at least in part, 
a component of the suppressive machinery of T reg cells 
is supported by the independent demonstration of CD73 
expression by T reg cells (26). Adenosine exerts its eff  ects by 
binding to adenosine type 1 purinergic G protein–coupled 
cell surface receptors, which are termed A1, A2a, A2B, and 
A3. Adenosine is a potent inhibitor of T cell responses (19), 
and the A2A receptor has been identifi  ed as the major anti-
infl  ammatory adenosine receptor associated with T cells (21).
The expression patterns of the A2A receptor were evalu-
ated in T reg cells and CD4+/CD25− cell populations. Under 
resting conditions, the highest A2A mRNA levels are present 
in T reg cells, which, in the presence of adenosine generated 
from CD39, may account for the anergic state typical of this 
population. Minimal A2A mRNA expression could be de-
tected in CD4+/CD25− cells (Fig. 4 A), but eff  ector T cells 
acquire A2A receptors during activation, starting at 4 d after 
stimulation and with expression peaking at day 6 (Fig. 4 A). 
Figure 3.  Concomitant expression of CD39/CD73 and generation of 
adenosine distinguishes T reg cells from other T cells. (A) CD39/NTPDase 
activity in CD4+/CD25+ and CD4+/CD25− cells. (B) Hydrolysis of extracel-
lular 14C-radiolabeled ADP to adenosine is catalyzed by WT CD4+ (lanes 4–8) 
but not Cd39-null CD4+ (lanes 9–13) mouse T cells. The radiolabeled stan-
dards are designated as ADP, AMP, and Adenosine (lanes 1–3). (C) Hydrolysis 
of extracellular ADP by Foxp3+/CD39+ (fi  rst to fi  fth lanes), Foxp3−/CD39+ 
(6th to 10th lanes), and Foxp3−/CD39− (11th to 15th lanes) cells.1262  GENERATION OF ADENOSINE BY T REG CELLS | Deaglio et al. 
Little or no expression of A2B receptors is identifi  ed in 
T cells (unpublished data). To determine whether signaling 
through the A2A receptor has functional consequences in 
CD4+/CD25− cells, a panel of adenosine agonists with de-
fi  ned selectivity toward the full array of adenosine receptors 
was tested. The proliferation of CD4+/CD25− cells stimu-
lated by allogeneic cells in culture was substantially inhibited 
in a dose-dependent fashion in the presence of A2A-specifi  c 
agonists (ATL146e), confi   rming a potent pharmacological 
  eff  ect (Fig. 4 B). Much weaker eff  ects were obtained using 
compounds with somewhat nonselective A1 and A3 receptor 
agonist activity (Fig. 4 C).
The central role of adenosine generation in the control 
of CD4+/CD25− proliferation was then tested by using lym-
phocytes from mutant mice null for A2A receptors. We noted 
that A2A-null CD4+/CD25− proliferation rates in response 
to TCR stimulation in the presence of irradiated accessory 
cells are markedly increased by day 6 (Fig. 4 D). These obser-
vations are in agreement with the known kinetics of A2A re-
ceptor up-regulation and validate further previous observations 
regarding A2A receptor properties in T eff  ector cells (21). The 
timing of up-regulation of the A2A receptor during T cell 
  activation suggests that this novel immunosuppressive loop is 
functional during the late phases of T eff  ector cell activation 
and proliferation, likely coinciding with maximal nucleotide 
leak from increasingly hypoxic or activated cells (30).
Effects of CD39 upon adenosinergic loops that comprise 
a component of the suppressive machinery of T reg cells
CD39 critically regulates levels of ADP (Fig. 3 B), a crucial 
feed-forward inhibitor of CD73 (31). Therefore, we further 
studied Cd39-null mice to determine how disruption of the 
ectonucleotidase cascade impacts T reg cell functions. Cd39-
null mice express CD4+/CD25+ T cells in the expected num-
bers in peripheral blood and lymphoid organs. These cells 
express traditional markers of T reg cells, such as Foxp3 and 
GITR. However, T reg cells isolated from Cd39-null ani-
mals display features consistent with an activated state, such as 
enhanced mRNA expression of CD25 and CTLA-4 (Fig. 5 A). 
These features possibly refl  ect aberrant purinergic signaling, 
resulting in the loss of any putative inhibitory adenosinergic 
autocrine loop. Moreover, Cd39-null T reg cells are mark-
edly dysfunctional in other ways: specifi  cally, they are not 
anergic and proliferate excessively in response to anti-CD3 
and anti-CD28 triggering and to alloantigens without exog-
enous IL-2 (Fig. 5 B).
Concordant with data derived from A2A-null CD4+/
CD25− (Fig. 4 D), proliferation responses of CD4+/CD25− 
T cells obtained from Cd39-null mice are exaggerated after 
6 d of stimulation, which is coincident with the up-regulation 
of adenosine receptor A2A in CD4+/CD25− cells (Fig. 5 C). 
As a further confi  rmation of direct connections between 
CD39 expression and adenosine generation, eff  ects of the 
Figure 4.  Adenosine generated by CD39 and CD73 suppresses 
T cell proliferation. (A) mRNA expression of adenosine A2A receptor. 
Cells were activated for 5 d in vitro. Data are means of three indepen-
dent experiments. (B) ATL146e inhibits T cell proliferation in response 
to alloantigens. 5 × 104 CD4+/CD25− T cells were cultured alone or in 
the presence of irradiated allogeneic splenocytes (shaded bar) with 
ATL146e at indicated concentrations. Data are means with SEM (error 
bars) of more than fi  ve independent experiments (P < 0.05 vs. CD4+/
CD25− cells alone). (C) Inhibition of T cell proliferation by adenosine 
receptor agonists. C277, E2387, C7938, and ATL146e (1 μM fi  nal) were 
added at the beginning of the cultures. [3H]Thymidine incorporation 
was assayed at day 5. Data are representative of five independent 
experiments. (D) Proliferation of CD4+/CD25− T cells purifi  ed from 
A2A-null (black bars) or WT (white bars) mice and stimulated by 
2.5 μg/ml of plate-bound anti-CD3 and 2.5 μg/ml of soluble anti-CD28. 
[3H]Thymidine was added for the last 8 h of culture. Representative 
data are from three experiments. *, P < 0.002 between WT and A2A 
null at 6 d of culture.JEM VOL. 204, June 11, 2007  1263
BRIEF DEFINITIVE REPORT
addition of soluble exogenous NTPDases (apyrase grade VII) 
to Cd39-null T cell cultures were tested. This reconstitution 
eff  ectively suppresses the abnormal proliferation of CD4+/
CD25− cells (Fig. 5 C) and restores anergy within the T reg 
cell pool (not depicted).
We next examined the suppressive ability of WT and 
Cd39-null T reg cells to inhibit the proliferation of WT or 
Cd39-null eff  ector cells, respectively. An in vitro system 
was chosen whereby eff  ector cells were activated with anti-
CD3 and anti-CD28. This system was chosen to eliminate 
the expression of CD39 on stimulating cells, which con-
founds analyses. We found that Cd39-null T reg cells were 
50–60% less eff  ective at inhibiting Cd39-null eff  ector cell 
proliferation compared with WT counterparts at all ratios 
tested (unpublished data).
To further determine the importance of the CD39-
adenosinergic axis upon T cell function, we examined the 
ability of T reg cells from WT and Cd39-null animals to sup-
press the proliferation of CD4+/CD25− cells from WT and 
A2A-null mice. Although the elimination of Cd39 substan-
tially   retards adenosine generation, it does not account for 
local adenosine release. Therefore, we generated an in vitro 
system in which the cellular machinery that generates adeno-
sine or the dominant receptors that bind adenosine are intact 
or disrupted, respectively. Given the kinetics of A2A recep-
tor up-regulation (Fig. 4, A and D), this system was ana-
lyzed at day 5, a time point when, in the absence of T reg 
cells, almost all   eff  ector T cells have entered into prolifera-
tion. Under such conditions, Cd39-null T reg cells are  50% 
less eff  ective at suppressing A2A-null T cell proliferation 
when compared with the ability of WT T reg cells to suppress 
WT CD4+/CD25− proliferation when mixed at a ratio 
of 1:1 (Fig. 5 D). This eff  ect is shown by the increased num-
bers of A2A-null CD4+/CD25− T cells that have entered 
into proliferation. The disparity between the suppressive ca-
pacities of WT and Cd39-null T reg cells holds at decreased 
numbers relative to eff  ectors, with greater numbers of eff  ec-
tor T cells entering into proliferation at each reduced ratio 
(unpublished data). Interestingly, analysis of cultures at earlier 
time points failed to demonstrate a diff  erence in the suppressive 
ability between WT and Cd39-null T reg cells (unpublished 
data), once again indicating that Cd39 and the subsequent 
generation of adenosine are eff  ective late in the proliferation 
of T cells.
These data further imply that adenosine generated from 
the hydrolysis of nucleotides exerts substantive inhibitory 
  eff  ects primarily through the A2A receptor in vitro, which is 
additive to any other cell–cell contact putative mechanisms 
that dictate T reg cell function. CD4+/CD25+ T cells isolated 
from Cd39-null animals also exhibit attenuated suppressive 
capabilities in vivo, as assessed in a transplant rejection model 
in immune reconstituted mice. Here, WT and mutant T reg 
cells are transferred in excess with CD4+/CD25− T cells, and 
the capacity to prevent the rejection of skin allografts was 
  examined. As expected (32, 33), adoptive transfer of WT 
T reg cells with WT CD4+/CD25− cells at the well-defi  ned 
4:1 ratio results in long-term allograft survival (>40 d). In 
contrast, when Cd39-null T reg cells are transferred together 
with Cd39-null T eff  ectors at the same cellular ratios, four out 
of eight grafts are rejected at a median of 24.5 d (P = 0.02). 
Transfer of CD4+/CD25+ T cells alone from either WT or 
Figure 5.  T reg cells from Cd39-null mice are constitutively acti-
vated and fail to suppress CD4+/CD25− cell proliferation. (A) CD25 
and CTLA-4 mRNA expression in CD4+/CD25− and CD4+/CD25+ cells 
isolated from Cd39-null (black bars) or WT mice (white bars). (B) Prolifera-
tion assay of CD4+/CD25+ T cells purifi  ed from Cd39-null (black bars) or 
WT (white bars) mice. Cells were cultured in the presence or absence of 
2.5 μg/ml of plate-bound anti-CD3 and 2.5 μg/ml of soluble anti-CD28 
for 3 d. (C) Proliferation of CD4+/CD25− T cells purifi  ed from Cd39-null 
(black bars) or WT (white bars) mice cultured in the presence of irradiated 
allogeneic splenocytes. Apyrase reconstitution effects are noted at day 6 
(shaded bars). Error bars represent the SEM of three independent experi-
ments. (D) T reg cell function. Cd39-null T reg cell effects of the stimula-
tion of A2A-null Teff (open) and WT T reg cells on WT Teff (closed; 1:1 
ratio) are compared at day 5. A represents the nonproliferating cell popu-
lations, B represents CD4+/CD25− cells that have entered into the cell 
cycle, and C represents unlabeled T reg cells. The percentage of cells pre-
sent in A or B was quantifi  ed using FlowJo software. Data are representa-
tive of three independent experiments. (E) Skin allograft survival. C57BL/6 
Rag 1–defi  cient mice received allogeneic skin grafts 24 h after the passive 
transfer of CD4+/CD25+ and/or CD4+/CD25− cells from WT or Cd39-null 
mice in a ratio of 4:1 (32, 33). Mice receiving WT (circles) or Cd39-null 
(triangles) CD4+/CD25− cells rejected the skin graft at a median of 13 d 
(n = 6). Mice receiving WT CD4+/CD25+ cells transferred in excess 
(diamonds; 4:1) with WT CD4+/CD25− cells showed long-term graft 
survival (n = 9). Four out of eight mice receiving Cd39-null CD4+/CD25+ 
cells transferred in excess (squares; 4:1) with Cd39-null CD4+/CD25− cells 
rejected the skin allograft at a median of 24.5 d (P = 0.02). 1264  GENERATION OF ADENOSINE BY T REG CELLS | Deaglio et al. 
Cd39-null animals does not induce rejection (not depicted); 
no statistically signifi  cant diff  erences are observed in the rejec-
tion times induced by the transfer of WT or Cd39-null CD4+/
CD25− cells alone (Fig. 5 E). These results are the fi  rst dem-
onstration that the CD39-adenosinergic axis plays a non-
redundant role in CD4+/CD25− cell suppression mechanisms 
in vivo, giving credence to our phenotypic studies and other 
expression analyses (8). Our data strongly suggest that adeno-
sine generation is an important component of the T reg cell 
armamentarium and is essential for full suppressive function.
CD39 and CD73 are components of a larger family of ecto-
enzymes that degrade nucleotides and include molecules for 
which a clear-cut role in lymphocyte activation and migration 
has been extensively proven, such as CD26 (34) and CD38 
(35). All of these enzymes evolved from highly conserved an-
cestral proteins, usually acquiring membrane anchorage and 
developing parallel, albeit independent, functions. The acqui-
sition of receptor functions such as signal transduction, local-
ization in membrane lipid microdomains, and physical and 
functional association with partners specialized in signal trans-
duction are particularly relevant. Similar properties also have 
been shown, albeit in a more limited manner for CD39 (36).
Conclusion
Our data demonstrate that CD39 is a novel cell surface 
marker of Foxp3 T reg cells. Functionally, the coexpression 
of CD39 and CD73 with the pericellular generation of aden-
osine dictates a substantial component of the suppressive ca-
pabilities of T reg cells. CD39 might regulate immune T cell 
suppression by the downstream production of adenosine act-
ing via the A2A receptor. Advances in the understanding of 
how CD39 impacts T reg cell suppressive functions may help 
develop novel therapeutic avenues to target common infl  am-
matory and immune disorders.
MATERIALS AND METHODS
Mice. Mice used in this study are as follows: Cd39 null (29), FoxP3 knock-
in (28); DBA/2, C57BL/6 Rag 1–defi  cient mice (Jackson ImmunoResearch 
Laboratories); A2A null (Boston University Medical Center), and littermate 
controls. Beth Israel Deaconess Medical Center Institutional Animal Care 
and Use Committee (Animal Ethics Committee) approval was obtained for 
all experimental work.
Cell preparations. Cells were positively selected using MACS (Miltenyi 
Biotec) or MoFlow cell sorter (BD Biosciences) or were purifi  ed using the 
mouse CD4+/CD25+ isolation kit (Miltenyi Biotec). Cells from Foxp3 
knock-in animals were sorted on the basis of GFP fl  uorescence.
Antibodies and reagents. The following antibodies were used: rabbit 
α–mouse CD39 polyclonal antibody (27), FITC- and PE-conjugated goat 
α–rabbit Ig (Jackson ImmunoResearch Laboratories), α–mouse CD4, CD8, 
B220, CD25, CD5, CD73, CD62L, and CD45RB (eBioscience), and α–mouse 
CD3 and CD28 (BD Biosciences). Adenosine receptor agonists used in this 
study were CGS-21680, NECA, C7938, C277 (Sigma-Aldrich), and ATL146e 
(Adenosine Therapeutics).
Quantitative TaqMan real-time PCR. A sequence detection system 
(ABI PRISM 7900HT; Applied Biosystems) was used for real-time PCR 
analysis. Primer-probe sets and TaqMan Universal PCR Master Mix were 
purchased from Applied Biosystems. Gene expression was analyzed against 
mouse GAPDH.
ATPase and ADPase assays. 5 × 104 CD4+/CD25+ or CD4+/CD25− 
cells were isolated and washed three times in cold phosphate-free buff  er. 
Cells were warmed in incubation buff  er (10 mM glucose, 20 mM Hepes, pH 
7.5, 5 mM KCl, 120 mM NaCl, 2 mM CaCl2, and 5 mM tetramisole) to 
37°C for 10 min. Cells were then incubated in the same buff  er with 2 mM 
ATP for 10 min. Reactions were stopped with the addition of trichloroacetic 
acid to a fi  nal concentration of 5% and immediately put on ice. Phosphate con-
centration was measured after the addition of Malachite green/polyvinyl 
alcohol/ammonium molybdate solution for 20 min by a spectrophotometer 
(ELx808 Ultra Microplate Reader; Bio-Tek Instruments, Inc.) at 610 nm 
and compared against a standard curve.
TLC. 2 mCi/ml [14C]ADP (Ge Healthcare) was added to cell cultures; 
aliquots were removed and analyzed for the presence of [14C]ADP hydrolysis 
products by TLC (three diff  erent cell culture preparations).
Functional assays. T cells (5 × 104/well) were cultured with irradiated 
DBA2 splenic leukocytes (2 × 105/well) or 2.5 μg/ml plate-bound α-CD3 
and 2.5 μg/ml soluble α-CD28. CD4+/CD25+ or CD4+/CD39+ T cells were 
mixed with 5 × 104 CD4+/CD25−, CD4+/CD39−, or CD4+/CD25−/
CD39− T cells in the presence of irradiated syngeneic splenocytes depleted 
of CD3+ cells and supplemented with 5 μg/ml α-CD3. Data are expressed 
as mean counts per minute in triplicate wells. WT or Cd39-null T reg cells 
were mixed with WT or A2A-null CD4+/CD25− that was previously labeled 
with 5 μM CFSE (Invitrogen), stimulated with α-CD3 and α-CD28, and 
analyzed by FACS.
Adoptive transfer experiments. T cells from Cd39-null or WT mice 
were transferred into C57BL/6 Rag 1–defi  cient mice. The next day, mice 
received an allogeneic skin graft from BALB/c mice. Grafts were considered 
to be rejected when  60% of the graft was destroyed.
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